 JENA, Germany, Oct. 12, 2021 GLOBE NEWSWIRE -- InflaRx N.V. Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the completion of enrollment of the Phase III part of the Phase IIIII vilobelimab study in severe COVID-19 patients. 